Vrije Universiteit Brussel

Vib Vzw

Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw

Innogenetics N.v.

N.v. Innogenetics S.a.

501 N.v. Innogenetics

Patrick De Baetselier

Geert Raes

Nick Devoogdt

Tony Lahoutte

Jo Van Ginderachter

Steve Schoonooghe

Damya Laoui

Kiavash Movahedi

Peter Vanlandschoot

Erwin Sablon

Rudolf Lucas

Jens De Vos

Lucia Fransen

Hilde Revets

Gholamreza Hassanzadeh Ghassabeh

Rudolph Lucas

Pierre Cornelis

Alain Beschin

Lucie Fransen

Alain Bloc

Jérôme Pugin

Simon Tierens

Gezim Bala

Sophie Hernot

Ines Cabrito

Benoît Stijlemans

Amanda Sparkes

The present invention relates to immunoglobulin single variable domains that bind MIF and more in particular to polypeptides that comprise or essentially consist of one or more such immunoglobulin single variable domains; to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.

Immunoglobulin single variable domains directed against macrophage migration inhibitory factor

The disclosure relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.

Targeting and in vivo imaging of tumor-associated macrophages

The disclosure relates to the field of cardiovascular diseases. In particular, immunoglobulin single variable domains directed against macrophage mannose receptor (MMR) are provided that can be used in the diagnosis, prognosis and/or monitoring of cardiovascular diseases or as therapeutics. Also, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are useful at different stages of cardiovascular diseases, including post-infarction cardiovascular events. Further, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are particularly useful for the in vivo targeting and/or imaging of vulnerable atherosclerotic plaques.

Method of imaging a cardiovascular disease with an anti-macrophage mannose receptor immunoglobulin single variable domain

The disclosure relates to immunoglobulin single variable domains directed against human macrophage mannose receptor (MMR) and their uses in the field of oncology. More specifically, it concerns immunoglobulin single variable domains, including single-domain antibodies (sdAbs), against human MMR and their use in targeting and in vivo imaging of tumor-associated macrophages, with applications in the field of cancer diagnostics and therapeutics and monitoring of the disease.

Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages

The invention relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.

The present invention relates to novel markers for alternatively activated macrophages. More specifically, the present invention relates to the use of galactose-type C-type lectins as surface markers that allows rapid identification and sorting of the alternative macrophages. Such identifications can be useful in diseases where there is an imbalance between proinflammatory and anti-inflammatory immune reactions.

Markers for alternatively activated macrophages

The present invention is based on the finding that peptides derived from a specific domain of tumor necrosis factor-alpha (TNF-&#x3b1;) can efficiently be used to treat oedema. More specifically, the present invention relates to the usage of peptides derived from the region of human TNF-&#x3b1; from Serto Gluto treat pulmonary oedema. For example, the circularized peptide having amino acid sequence CGQRETPEGAEAKPWYC is shown to be very efficient in inducing oedema resorption.

TNF-derived peptides for use in treating oedema

The invention concernspolypeptides and peptides, particularly recombinant polypeptides, which are useful in tumour therapy, microbial infection, inflammation or immunology. The invention also relates to a process for preparing the above-mentioned polypeptides and peptides. Furthermore the invention concerns nucleic acids coding for said polypeptides and peptides.

[object Object]

The present invention relates to the use of the major OprI lipoprotein ofto elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of OprI&#x2014;antigen fusion proteins to elicit the Type-1 response. More particularly, the present invention is directed to pharmaceutical formulations comprising OprI and/or OprI fusion proteins, optionally together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.

Th1 inducing natural adjuvant for heterologous antigens

TNF-alpha muteins and a process for preparing them

The property of phagocyte cells to show chemiluminescence when activated by certain chemical or immunological agents is used for a qualitative and quantitative analysis of such agents in biological fluids. A variety of factors such as opsonizing anti-bodies, complement, inhibitors, membrane-specific anti-bodies, and their antigens, membrane-specific lectins, lymphokines, endotoxins, toxic substances and others can be analyzed in this way. The new method finds application in the biotechnical, clinical, immunological and pharmacological fields, with a special preference for toxicological screening of pharmaceuticals. The phagocyte cells needed for the analysis can be derived from a continuous phagocyte cell line and a method of producing such a cell line is provided.

Analytical utilization of phagocyte cell lines

Growing community of inventors

Berchem, Belgium

Patrick De Baetselier